Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Lysosomal Acid Lipase Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01307098
Recruitment Status : Completed
First Posted : March 2, 2011
Last Update Posted : July 27, 2016
Information provided by (Responsible Party):
Alexion Pharmaceuticals